{"id":"NCT02476006","sponsor":"Sanofi","briefTitle":"Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)","officialTitle":"A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-06-23","primaryCompletion":"2019-04-12","completion":"2019-04-12","firstPosted":"2015-06-19","resultsPosted":"2020-03-30","lastUpdate":"2022-03-28"},"enrollment":998,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"ALIROCUMAB SAR236553 (REGN727)","otherNames":["PraluentÂ®"]},{"type":"DRUG","name":"placebo (for injection training only)","otherNames":[]},{"type":"DRUG","name":"ezetimibe","otherNames":[]},{"type":"DRUG","name":"atorvastatin","otherNames":[]},{"type":"DRUG","name":"rosuvastatin","otherNames":[]},{"type":"DRUG","name":"simvastatin","otherNames":[]}],"arms":[{"label":"Alirocumab","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo provide participants with severe hypercholesterolemia at risk for subsequent cardiovascular (CV) events and not adequately controlled with currently available lipid-modifying therapy (LMT) access to alirocumab ahead of commercial availability and to document the overall safety and tolerability of alirocumab in this participant population.\n\nSecondary Objectives:\n\nTo document the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels as well as non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol (total-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels after 12 weeks of treatment.\n\nTo document participant's acceptability of self-injection (Self Injection Assessment Questionnaire, SIAQ).","primaryOutcome":{"measure":"Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"From first injection of investigational medicinal product (IMP) up to 2 weeks after last dose of study drug (Week 120)","effectByArm":[{"arm":"Alirocumab","deltaMin":71.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":null},"locations":{"siteCount":153,"countries":["Austria","Belgium","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hungary","Poland","Romania","Slovakia","Slovenia","Spain","Switzerland"]},"refs":{"pmids":["36064689"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":161,"n":994},"commonTop":["Nasopharyngitis","Myalgia","Headache","Influenza"]}}